silicontap
Startup News and Information for Silicon Valley
Home
Mobile
News and Events
  • Headlines
  • Events
  • Jobs
    		•
    Members Only
  • Networking
  • Venture Deals
  • Venture Firms
  • Companies
  • People
  • Exits
  • VentureMap
  • PowerSearch
  • FundingSearch
  • Stats
  • Dashboard
  • Satellite
  • Post Jobs
    • About
  • About
  • Contact Us
    		•
    Search News
    Monday, April 7, 2008

    Quark Pharmaceuticals Gets $27M


    Fremont-based Quark Pharmaceuticals has raised $27M in private financing, the firm said Monday. The investment came from the investment vehicles of SBI Asset Management Co., Ltd. and SBI Investment Co., Ltd., subsidiaries of SBI Holding Inc. Quark said the funding will go toward clinical studies of its RNAi drug piepeline. Quark Pharmaceuticals is developing and developing drug candidates based on siRNA; the firm's lead compound is AKIi-5, which is targeted at prevention of acute kidney injury (AKI) following major cardiac surgery. The firm said its AKi-5 compound is in Phase I/IIa clinical trials.
    posted on Monday, April 7, 2008 (Link to more information)


    Related companies:
    Quark Pharmaceuticals

    Related stories:
    > Quark Biotech Files For IPO
    > Arriva Pharmaceuticals Adds $6M
    > MAP Pharmaceuticals Sets IPO Pricing
    > Bridge Pharmaceuticals Raises $35M
    > Presidio Pharmaceuticals Gets $26M

    RSS subscri be via emailEmail Twitter


    Previous Issues

    Monday, February 8, 2010
    Friday, February 5, 2010
    Thursday, February 4, 2010
    Wednesday, February 3, 2010
    Tuesday, February 2, 2010